Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (August 2021)
17 slides from Tela Bio's investor presentation, Aug 11, 2021
Slide 1: Advancing Soft Tissue Reconstruction
Advancing Soft Tissue Reconstruction Investor Presentation August 2021
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding pos
Slide 3: Redefining soft tissue reconstruction with a differentiated category of tissue reinforcement materials
Redefining soft tissue reconstruction with a differentiated category of tissue reinforcement materials ~$2B U.S Market Opportunity 1 in hernia repair , abdominal wall reconstruction and plastic and reconstructive surgery 3 Innovative Products Compelling Clinical Evidence Products Offer Attractive Va
Slide 4: Creating Advanced Biologic Materials
4 Creating Advanced Biologic Materials Novel Biologic Tissue (derived from sheep) Polymer Fibers (permanent or resorbable) Innovative Textile Engineering Purposefully designed to address shortcomings & unmet clinical needs Issued patents protect underlying biologic tissue and product design Hernia &
Slide 5: OviTex: ~$1.5 Billion Annual U.S. Hernia Market Opportunity
5 OviTex: ~$1.5 Billion Annual U.S. Hernia Market Opportunity Simple Ventral Hernia Repair Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~58,000 ~326,000 ~711,000 ~40,000 $350M $500M $650M $40M Source: Millennium Re
Slide 6: Ventral Hernia Patients Range in Complexity
6 Ventral Hernia Patients Range in Complexity • CDC Wound Class I (clean) • Healthier patients - no co - morbidities • Primary hernia repair • CDC Wound Class II (clean - contaminated) • Patient co - morbidities (i.e., obesity, diabetes, COPD) • May have prior hernia repair failure • CDC Wound Class
Slide 7: Current Ventral Hernia Treatment Options: No Perfect Product
7 Current Ventral Hernia Treatment Options: No Perfect Product Persistent inflammatory response Encapsulation of implant Chronic post operative pain Scar tissue / lack of remodeling Mesh infections Significant costs of re - operation Organ erosion or perforation 6,000 related U.S. lawsuits PERMANENT
Slide 8: Growing Need for Alternative to Permanent Synthetic Mesh
8 Lawsuits against permanent synthetic meshes estimated to be assembled across the U.S. 2 of surgeons agree that use of permanent synthetic mesh puts patients at long - term risk of complications 1 Growing Need for Alternative to Permanent Synthetic Mesh 1 Hernia and Abdominal Surgeries Survey (Oct
Slide 9: OviTex Reinforced Tissue Matrix: a More Natural Hernia Repair
9 OviTex Reinforced Tissue Matrix: a More Natural Hernia Repair 䉼 An innovative reinforced tissue matrix designed to reduce stretch compared to biologic matrices and long - term complications experienced with resorbable and permanent synthetic meshes Unique permeable design facilitates rapid fluid t
Slide 10: OviTex LPR for Laparoscopic & Robotic Hernia Repair
10 OviTex LPR for Laparoscopic & Robotic Hernia Repair Tailored OviTex product designed for improved handling in MIS techniques and trocar accessibility Our Solution: OviTex LPR Increase in Robotic - Assisted Hernia Repair ▫ Surgeons have adopted robotic - assisted techniques, primarily for inguinal
Slide 11: Compelling Clinical Evidence
11 Compelling Clinical Evidence Ventral Hernia Inguinal Hernia Hiatal Hernia Presentations / Publications 18 Presentations / Publications 5 Presentations / Publications 4 Low incidence of chronic post - operative pain Low hernia recurrence Low SSO / SSI Ease of use Low rate of surgical site occurren
Slide 12: OviTex PRS: ~$500 Million Annual U.S. Plastic & Reconstructive Surgery Market Opportunity
12 OviTex PRS: ~$500 Million Annual U.S. Plastic & Reconstructive Surgery Market Opportunity $500M 1 Market dominated by human acellular dermal matrices (HADMs) ▫ Prone to high degree of stretch ▫ Expensive, putting pressure on hospital systems ▫ Often experience supply shortages, particularly when
Slide 13: OviTex PRS: Purposely Designed for Plastic and Reconstructive Surgery
13 OviTex PRS: Purposely Designed for Plastic and Reconstructive Surgery Layers of biologic material enable functional tissue remodeling Corner - lock diamond embroidery pattern allows the product to stretch while maintaining its shape Fenestrations and slits facilitate fluid management, allow for r
Slide 14: Commercial Organization
14 Commercial Organization 45 sales territories as of June 30, 2021 ▫ OR - based Account Managers call on General, Plastic Recon, Colorectal & Trauma surgeons ▫ Carry full OviTex & OviTex PRS portfolios 6 sales regions ▫ Plan to scale existing regions until each region has ~8 territories ▫ Supported
Slide 15: Growth Strategy
15 Growth Strategy ▫ Promote broader awareness of OviTex & OviTex PRS products ▫ Employ virtual sales & marketing programs, including TELA LIVE ▫ Drive market awareness of risks of permanent synthetic mesh use ▫ Publish BRAVO clinical data INCREASE ADOPTION ▫ Scale direct sales force ▫ Drive account
Slide 16: Delivering Revenue Growth / Q2 2021 Performance
16 $3.7 $3.5 $5.9 $7.6 Q1 Q2 Q2 2021 Performance ▫ Revenue growth of 116% year over year, up 29% from Q1:21 ▫ Cash and Cash equivalents (as of June 30, 2021): $60.3M ▫ Robotic and MIS hernia procedures represent over 50% of all OviTex hernia procedures Delivering Revenue Growth ($ millions) Annual R
Slide 17: Investment Highlights
17 Investment Highlights Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence Focused on ~$2.0 billion annual U.S. total addressable markets Driving commercial adoption with targeted direct - sales approach Recent product launches in growing markets: robotic hernia s